Thursday, May 24, 2012
A team from The
Johns Hopkins University has clinical proof of concept
for an unconventional approach to slowing the progression of Alzheimer's
disease-reducing activity in the hippocampus with antiepileptic drugs.1
Based on the findings, AgeneBio Inc. has licensed patent
applications from the university on lowering brain activity with antiepileptic
drugs to prevent AD.
Osherovich, L. SciBX 5(21);
Published online May 24, 2012
1. Bakker, A. et al. Neuron; published online May 10, 2012;
Contact: Michela Gallagher, The Johns Hopkins University,
2. Wilson, I.A. et al. J. Neurosci. 25, 6877-6886
3. Minkeviciene, R. et al. J. Neurosci. 29, 3453-3462
AND INSTITUTIONS MENTIONED
AgeneBio Inc., Carmel, Ind.
Gladstone Institute of Neurological Disease, San Francisco, Calif.
The Johns Hopkins University, Baltimore, Md.
UCB Group (Euronext:UCB), Brussels, Belgium
University of California, San Francisco, Calif.
Washington University in St. Louis, St. Louis, Mo.